<DOC>
	<DOCNO>NCT02751177</DOCNO>
	<brief_summary>RAS genotyping mandatory prescription anti-EGFR ( epidermal growth factor receptor ) therapies patient metastatic colorectal cancer . The standard genotyping assess formalin-fixed paraffin embed tumour tissue . This study compare RAS BRAF genotyping result achieve analyze circulate plasma DNA use OncoBEAM™ technique achieve use standard genotyping technique formalin-fixed paraffin embed sample .</brief_summary>
	<brief_title>Detection KRAS , NRAS et BRAF Mutations Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The study propose patient metastatic colorectal cancer . Study information give patient routine medical examination . The patient include check inclusion criterion signature inform consent form Blood sampling ( 30 ml ) perform initiation first line metastatic chemotherapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Adult subject newly diagnose , anti EGFR treatment naïve metastatic colorectal cancer Standard Care RAS/RAF test perform FFPE tumor sample part routine Patient information write informed consent form sign Patient must affiliate social security system Age : 18 year old Patient bear nonmetastatic colorectal cancer Patient local relapse Patient exclusive nodal metastasis Patient whose health contraindicate 30 ml blood sample Blood transfusion within 1 week prior blood collection Patient receive chemotherapy / radiotherapy within 15 day prior blood collection History another primary cancer within last 5 year , exception nonmelanomatous skin cancer carcinoma situ cervix Persons deprive liberty supervision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>KRAS gene mutation</keyword>
	<keyword>NRAS gene mutation</keyword>
	<keyword>BRAF gene mutation</keyword>
</DOC>